Guggenheim initiated coverage of Icosavax with a Buy rating and $28 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ICVX:
- Icosavax reports Q3 EPS (44c), consensus (57c)
- Icosavax, Inc. (ICVX) Q3 Earnings Cheat Sheet
- Icosavax to Participate in the Jefferies London Healthcare Conference
- Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference
- Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023